Tepotinib (Tetmeko) will shortly be assessed by the Scottish Medicines Consortium (SMC) for use in NHS Scotland, and we are invited to provide a Patient Group Submission for the medicine.
The indication this new medicine will be assessed under is 'For use in adults to treat a type of lung cancer, called non-small cell lung cancer (NSCLC) that has certain abnormal changes in the mesenchymal-epithelial transition factor gene (MET), known as MET exon 14 (METex14) skipping alterations, and which has spread beyond the lungs and/or cannot be removed by surgery.'
We are looking for anyone that has a lung cancer mutation named MET exon14 (METx14) skipping mutation. We would like to hear your experience of this and or any treatment options you have been given.
We do not need to include any personal details in the submission. But speaking to those with experience of the treatment and obtaining quotes for the submission is the most important part of the submission.
If you would like to reply you can do so in response to this post or email ask the nurse at lungcancerhelp@roycastle.org or call our free phone nurse led helpline number on 0800 358 7200 Monday to Thursday 0900-1700 and Friday 0900-1600
Kind regards
The Roy Castle Support Team
Patient experience of Atezolizumab (Tecentriq)
Have you recently been diagnosed with lung cancer?
What to expect when you have little information
Do you have any helpful \"Hints and Tips\" for people living with lung cancer?
